CATA-002
/ Ab Studio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 03, 2026
Preclinical Evaluation of CATA-002, a Novel Aβ/TfR Bispecific Brain-Shuttled Catalytic Antibody for Enhanced Brain Penetration and Enzymatic Aβ Degradation in Alzheimer's Disease
(CTAD 2026)
- No abstract available
Bispecific • Preclinical • Alzheimer's Disease • CNS Disorders
1 to 1
Of
1
Go to page
1